Share
2,196 Posts.
lightbulb Created with Sketch. 644
clock Created with Sketch. 29/06/22
11:41
Share
Originally posted by bedger
↑
Hilarious isn't it? It was with some 'fear' I sold my tech stocks in the US late 2021 with admittedly very poor grasp on measuring exuberance. I just knew they were ridiculously valued, but then again, they were half a year before too! OCC had long been under-valued given its products. Then it started looking a bit shaky with management's ability to commercialise, hence the price falls. I don't know where the 2H 2022 low is in OCC, but I do know its ridiculously under-valued with this deal and these prices.This company has gone from very much from needing a capital raising come year end if they had not negotiated this or another deal, to now having some 15 quarters worth of cash at their present run rate, whilst the revenues from BioHorizons sales moving them towards positive free cash flow anyway and certainly that cash run rate will be signficantly reduced by manufacturing revenues.
Expand
Another covert educational post for the dimwitted. Good one. And I totally concur, mate. Being short on time I will be succinct. Until the market can get a handle on what the margins will be, I believe institutional investment will allude us. Only once we see a some inflows will the sp conform to our standpoint.
(20min delay)